Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed relapsed/recurrent or refractory indolent lymphoproliferative disorder of 1 of the following types:
• •* Chronic lymphocytic leukemia
• •* Absolute lymphocytosis greater than 5,000/mm\^3
• •* B-cell phenotype (CD 19, 20, or 23 positive) with more than 30% bone marrow lymphocytes
• •* B-cell small lymphocytic lymphoma
• •* Marginal zone B-cell lymphoma
• •* Grade I-III follicle center cell lymphoma
• •* Waldenstrom's macroglobulinemia
• •* Mantle cell lymphoma
• •At least 1 unidimensionally measurable lesion for patients with non-Hodgkin's lymphoma
• •* At least 2 cm by conventional techniques
• •No active brain metastases
• •* Treated CNS disease allowed
• •PATIENT CHARACTERISTICS:
• •Age
• •18 and over
• •Performance status
• •Karnofsky 60-100%
• •Life expectancy
• •At least 3 months
• •Hematopoietic
• •Absolute neutrophil count ≥ 1,000/mm\^3 (500/mm\^3 if there is lymphomatous involvement of the bone marrow)
• •Platelet count ≥ 50,000/mm\^3
• •Hepatic
• •Bilirubin ≤ 1.5 times upper limit of normal (ULN)
• •AST or ALT ≤ 2.5 times ULN (4 times ULN if there is liver involvement)
• •Renal
• •Creatinine ≤ 2 times ULN OR
• •Creatinine clearance ≥ 50 mL/min
• •Cardiovascular
• •No history of orthostatic hypotension
• •No myocardial infarction, cerebrovascular accident, or transient ischemic attack within the past 3 months
• •No New York Heart Association class III or IV congestive heart failure
• •No unstable angina pectoris
• •No cardiac arrhythmia
• •No uncontrolled hypertension requiring manipulation of antihypertensive medications
• •No evidence of any of the following by echocardiogram:
• •* Acute ischemia
• •* Significant conduction abnormality
• •* Bifascicular block
• •* 2\^nd- or 3\^rd-degree atrioventricular block
• •Other
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •HIV negative
• •No other immunodeficiency
• •No known severe hypersensitivity reaction to agents containing Cremophor EL
• •No ongoing or active infection
• •Febrile episodes up to 38.5° Celsius allowed in the absence of infection
• •No other concurrent uncontrolled illness that would preclude study participation
• •No psychiatric illness or social situation that would preclude study compliance
• •No preexisting grade II or greater sensory neuropathy
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •At least 3 months since prior monoclonal antibodies (unless there is clearly documented evidence of disease progression after therapy)
• •At least 3 months since prior radioimmunotherapy
• •No prior allogeneic bone marrow transplantation
• •Chemotherapy
• •At least 4 weeks since prior cytotoxic chemotherapy (6 weeks for mitomycin, nitrosoureas, or carmustine) and recovered
• •No more than 4 prior chemotherapy regimens (including high-dose chemotherapy \[HDC\] for patients with relapsed disease \> 100 days after completion of HDC)
• •* Cytoreduction plus HDC is considered 1 chemotherapy regimen
• •No other concurrent chemotherapy
• •Endocrine therapy
• •At least 7 days since prior steroids
• •Radiotherapy
• •More than 3 weeks since prior radiotherapy and recovered
• •No concurrent radiotherapy
• •Surgery
• •More than 4 weeks since prior major surgery
• •Other
• •Use of antibiotics for marginal zone lymphoma does not count as a prior therapy
• •No other concurrent investigational agents
• •No other concurrent anticancer therapy